Education
About Us
Working with TipRanks
Follow Us
Resverlogix Corp. (TSE:RVX)
:RVX
RVX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.30
Previous CloseN/A
Volume1.00K
Average Volume (3M)86.42K
Market Cap
C$28.67M
Enterprise ValueC$113.18M
Total Cash (Recent Filing)C$95.00K
Total Debt (Recent Filing)C$6.77M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding286,737,700
10 Day Avg. Volume71,654
30 Day Avg. Volume86,423
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-0.44
Price to Sales (P/S)0.00
P/FCF Ratio-6.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Resverlogix News
RVX FAQ
What was Resverlogix Corp.’s price range in the past 12 months?
Resverlogix Corp. lowest stock price was C$0.04 and its highest was C$0.30 in the past 12 months.
What is Resverlogix Corp.’s market cap?
Resverlogix Corp.’s market cap is C$28.67M.
When is Resverlogix Corp.’s upcoming earnings report date?
Resverlogix Corp.’s upcoming earnings report date is Nov 07, 2025 which is in 42 days.
How were Resverlogix Corp.’s earnings last quarter?
Resverlogix Corp. released its earnings results on Aug 14, 2025. The company reported -C$0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.008.
Is Resverlogix Corp. overvalued?
According to Wall Street analysts Resverlogix Corp.’s price is currently Overvalued.
Does Resverlogix Corp. pay dividends?
Resverlogix Corp. does not currently pay dividends.
What is Resverlogix Corp.’s EPS estimate?
Resverlogix Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Resverlogix Corp. have?
Resverlogix Corp. has 286,737,700 shares outstanding.
What happened to Resverlogix Corp.’s price movement after its last earnings report?
Resverlogix Corp. reported an EPS of -C$0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.333%.
Which hedge fund is a major shareholder of Resverlogix Corp.?
Currently, no hedge funds are holding shares in TSE:RVX
Resverlogix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.62%
Trailing 12-Months
Company Description
Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
Technical Analysis
Kane Biotech
―
Britannia Life Sciences Inc
―
―
BetterLife Pharma
―
BioVaxys Technology Corp
―
Options Prices
Currently, No data available
---